These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 11307806

  • 1. Impact of apolipoprotein(a) isoform size heterogeneity on the lysine binding function of lipoprotein(a) in early onset coronary artery disease.
    Simó JM, Joven J, Vilella E, Ribas M, Pujana MA, Sundaram IM, Hammel JP, Hoover-Plow JL.
    Thromb Haemost; 2001 Mar; 85(3):412-7. PubMed ID: 11307806
    [Abstract] [Full Text] [Related]

  • 2. Association between apolipoprotein(a) phenotypes and coronary heart disease at a young age.
    Gazzaruso C, Garzaniti A, Buscaglia P, Bonetti G, Falcone C, Fratino P, Finardi G, Geroldi D.
    J Am Coll Cardiol; 1999 Jan; 33(1):157-63. PubMed ID: 9935023
    [Abstract] [Full Text] [Related]

  • 3. Identification of sequences in apolipoprotein(a) that maintain its closed conformation: a novel role for apo(a) isoform size in determining the efficiency of covalent Lp(a) formation.
    Becker L, Cook PM, Koschinsky ML.
    Biochemistry; 2004 Aug 10; 43(31):9978-88. PubMed ID: 15287725
    [Abstract] [Full Text] [Related]

  • 4. Elevated Lp(a) with a small apo(a) isoform in children: risk factor for the development of premature coronary artery disease.
    Dirisamer A, Widhalm H, Aldover-Macasaet E, Molzer S, Widhalm K.
    Acta Paediatr; 2008 Dec 10; 97(12):1653-7. PubMed ID: 18684164
    [Abstract] [Full Text] [Related]

  • 5. Comparison of the effects of Apo(a) kringle IV-10 and plasminogen kringles on the interactions of lipoprotein(a) with regulatory molecules.
    Xue S, Green MA, LoGrasso PV, Boettcher BR, Madison EL, Curtiss LK, Miles LA.
    Thromb Haemost; 1999 Mar 10; 81(3):428-35. PubMed ID: 10102473
    [Abstract] [Full Text] [Related]

  • 6. Lipoprotein(a) plasma concentrations, apolipoprotein (a) polymorphism and family history of coronary heart disease in patients with essential hypertension.
    Gazzaruso C, Buscaglia P, Garzaniti A, Bonetti G, Savino S, Mariotti S, Jucci A, Finardi G, Geroldi D.
    J Cardiovasc Risk; 1996 Apr 10; 3(2):191-7. PubMed ID: 8836862
    [Abstract] [Full Text] [Related]

  • 7. High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients.
    Longenecker JC, Klag MJ, Marcovina SM, Liu YM, Jaar BG, Powe NR, Fink NE, Levey AS, Coresh J.
    J Am Soc Nephrol; 2005 Jun 10; 16(6):1794-802. PubMed ID: 15800123
    [Abstract] [Full Text] [Related]

  • 8. Polymorphisms in human apolipoprotein(a) kringle IV-10 and coronary artery disease: relationship to allele size, plasma lipoprotein(a) concentration, and lysine binding site activity.
    Simó JM, Joven J, Vilella E, Ribas M, Figuera L, Virgos C, Sundaram IM, Hoover-Plow J.
    J Mol Med (Berl); 2001 Jun 10; 79(5-6):294-9. PubMed ID: 11485023
    [Abstract] [Full Text] [Related]

  • 9. Significance of apolipoprotein(a) phenotypes in acute coronary syndromes: relation with clinical presentation.
    Emanuele E, Peros E, Minoretti P, D'Angelo A, Montagna L, Falcone C, Geroldi D.
    Clin Chim Acta; 2004 Dec 10; 350(1-2):159-65. PubMed ID: 15530473
    [Abstract] [Full Text] [Related]

  • 10. Apolipoprotein(a) isoform-specific changes of lipoprotein(a) after kidney transplantation.
    Kronenberg F, Lhotta K, König P, Margreiter R, Dieplinger H, Utermann G.
    Eur J Hum Genet; 2003 Sep 10; 11(9):693-9. PubMed ID: 12939656
    [Abstract] [Full Text] [Related]

  • 11. Baboon lipoprotein(a) binds very weakly to lysine-agarose and fibrin despite the presence of a strong lysine-binding site in apolipoprotein(a) kringle IV type 10.
    Belczewski AR, Ho J, Taylor FB, Boffa MB, Jia Z, Koschinsky ML.
    Biochemistry; 2005 Jan 18; 44(2):555-64. PubMed ID: 15641780
    [Abstract] [Full Text] [Related]

  • 12. Protein loss and genetic polymorphism of apolipoprotein(a) modulate serum lipoprotein(a) in CAPD patients.
    Wanner C, Bartens W, Walz G, Nauck M, Schollmeyer P.
    Nephrol Dial Transplant; 1995 Jan 18; 10(1):75-81. PubMed ID: 7724034
    [Abstract] [Full Text] [Related]

  • 13. Analysis of the apolipoprotein(a) size polymorphism in patients with systemic lupus erythematosus.
    Peros E, Geroldi D, Bugatti S, Caporali R, Rossi P, Montecucco C, D'Angelo A, Emanuele E.
    Int J Mol Med; 2005 Apr 18; 15(4):661-5. PubMed ID: 15754029
    [Abstract] [Full Text] [Related]

  • 14. The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate.
    Rader DJ, Cain W, Ikewaki K, Talley G, Zech LA, Usher D, Brewer HB.
    J Clin Invest; 1994 Jun 18; 93(6):2758-63. PubMed ID: 8201014
    [Abstract] [Full Text] [Related]

  • 15. [Relation of pentanucleotide repeat polymorphism of apolipoprotein (a) gene to plasma lipoprotein (a) level among Chinese patients with myocardial infarction and cerebral infarction].
    Liu X, Sun L, Li Z, Gao Y, Hui R.
    Zhonghua Yi Xue Za Zhi; 2002 Oct 25; 82(20):1396-400. PubMed ID: 12509922
    [Abstract] [Full Text] [Related]

  • 16. Apolipoprotein(a) isoforms in infarcted men under 60 years old.
    Calmarza P, Cordero J, Santos V, Vella JC.
    Clin Biochem; 2004 Oct 25; 37(10):911-8. PubMed ID: 15369723
    [Abstract] [Full Text] [Related]

  • 17. Influence of lipoprotein (a) levels and isoforms on fibrinolytic activity--study in families with high lipoprotein (a) levels.
    Falcó C, Estellés A, Dalmau J, España F, Aznar J.
    Thromb Haemost; 1998 Apr 25; 79(4):818-23. PubMed ID: 9580386
    [Abstract] [Full Text] [Related]

  • 18. The solution phase interaction between apolipoprotein(a) and plasminogen inhibits the binding of plasminogen to a plasmin-modified fibrinogen surface.
    Sangrar W, Gabel BR, Boffa MB, Walker JB, Hancock MA, Marcovina SM, Horrevoets AJ, Nesheim ME, Koschinsky ML.
    Biochemistry; 1997 Aug 26; 36(34):10353-63. PubMed ID: 9265615
    [Abstract] [Full Text] [Related]

  • 19. Apo(a) phenotyping and long-term prognosis for coronary artery disease.
    Baños-González MA, Peña-Duque MA, Anglés-Cano E, Martinez-Rios MA, Bahena A, Valente-Acosta B, Cardoso-Saldaña G, Angulo-Ortíz J, de la Peña-Díaz A.
    Clin Biochem; 2010 May 26; 43(7-8):640-4. PubMed ID: 20153741
    [Abstract] [Full Text] [Related]

  • 20. Apolipoprotein(a) phenotypes are reliable biomarkers for familial aggregation of coronary heart disease.
    Peros E, Geroldi D, D'Angelo A, Falcone C, Montagna L, Carabela M, Emanuele E.
    Int J Mol Med; 2004 Feb 26; 13(2):243-7. PubMed ID: 14719130
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.